Navigation Links
Next Breath Receives ISO/IEC 17025:2005 Accreditation from the American Association for Laboratory Accreditation
Date:2/19/2013

Baltimore, Maryland (PRWEB) February 19, 2013

Next Breath, LLC, a Specialty Contract Research Organization (CRO) with expertise in analytical testing of pulmonary, nasal drug, and ophthalmic delivery systems, announced today that the company received its ISO (the International Organization for Standardization) and IEC (the International Electrotechnical Commission) 17025:2005 accreditation from the American Association for Laboratory Accreditation (A2LA). Compliance with this standard provides a globally accepted basis for laboratory accreditation. The standard specifies the management and technical requirements to be met by testing and calibration laboratories in both the organization and management of quality.

The ISO/IEC 17025:2005 also covers testing and calibration performed using standard methods, non-standard methods, and laboratory-developed methods. This accreditation is another illustration of Next Breath’s commitment to quality and technical expertise, and adherence to the highest standards in quality management systems.

Julie Suman, President, says, “We are very pleased with this accreditation, which confirms Next Breath’s commitment to meeting and exceeding the highest quality standards. We work diligently to maintain regulatory standards and we have once again demonstrated our ability to sustain and continuously improve quality systems within our organization.”

About A2LA

A2LA is non-profit, non-governmental, public service, membership society. A2LA also offers programs for the accreditation of testing laboratories, calibration laboratories, inspection bodies, proficiency testing providers, medical testing laboratories, reference material producers and product certification bodies.

About Next Breath

Next Breath, a member of the AptarGroup, is a cGMP contract services organization for pharmaceutical, biotech and medical device companies that bring pulmonary, nasal, and ophthalmic drug products to market. Next Breath provides comprehensive solutions to the development processes from proof of concept to commercialization. Next Breath has led successful submissions for pulmonary and nasal drug products and devices in the US and international markets.

For more information please visit http://www.nextbreath.net or http://www.aptar.com

Contact Next Breath
Badre Hammond, MBA
+(1)352-642-2141 / badre(dot)hammond(at)nextbreath(dot)net

Read the full story at http://www.prweb.com/releases/2013/2/prweb10435177.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Breathe Better With Clarity Allergy Center
2. Medzilla.com Special Report: Unemployed Can Breathe a Little Freer After Supreme Court's Affordable Care Act Ruling
3. OsteoFab™ Patient Specific Cranial Device Receives 510(k) Approval
4. Discovery Labs Receives $30 Million Funding Commitment from Deerfield Management
5. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
6. OsteoVantage™ Receives Grant from the National Science Foundation
7. Avillion LLP Receives Initial Funding From Abingworth and Clarus
8. St. Mark’s School Receives $4.8 Million Gift from Tech Pioneer Graduate
9. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
10. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
11. BioNeutral Group Receives Positive Testing Results From A Global Independent Laboratory For Its Ygiene Sterilant Against Anthrax Spores
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):